These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 20154039)

  • 1. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype.
    Kelly PJ; Archbold P; Price JH; Cardwell C; McCluggage WG
    J Clin Pathol; 2010 Feb; 63(2):169-73. PubMed ID: 20154039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
    Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
    Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
    Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extremely high levels of CA19-9 and CA125 antigen in benign mucinous ovarian cystadenoma.
    Ye C; Ito K; Komatsu Y; Takagi H
    Gynecol Oncol; 1994 Feb; 52(2):267-71. PubMed ID: 7508878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum CA19-9 as a predictor of malignancy in primary ovarian mucinous tumors: a matched case-control study.
    Cho HY; Kyung MS
    Med Sci Monit; 2014 Jul; 20():1334-9. PubMed ID: 25073801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression of the cdx2 gene in benign intestinal-type mucinous ovarian tumors].
    Gaggero G; Sola S; Mora M; Fulcheri E
    Pathologica; 2003 Aug; 95(4):185-91. PubMed ID: 14577202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI appearances of borderline ovarian tumours.
    Bent CL; Sahdev A; Rockall AG; Singh N; Sohaib SA; Reznek RH
    Clin Radiol; 2009 Apr; 64(4):430-8. PubMed ID: 19264189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.
    Mann DV; Edwards R; Ho S; Lau WY; Glazer G
    Eur J Surg Oncol; 2000 Aug; 26(5):474-9. PubMed ID: 11016469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Borderline ovarian tumours: retrospective analysis of twenty-one cases.
    Saygili U; Uslu T; Erten O; Doğan E
    Eur J Gynaecol Oncol; 1998; 19(2):182-5. PubMed ID: 9611063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours.
    Fauvet R; Dufournet C; Poncelet C; Uzan C; Hugol D; Daraï E
    J Surg Oncol; 2005 Dec; 92(4):337-43. PubMed ID: 16299808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucin gene transcripts in benign and borderline mucinous tumours of the ovary: an in situ hybridization study.
    Boman F; Buisine MP; Wacrenier A; Querleu D; Aubert JP; Porchet N
    J Pathol; 2001 Mar; 193(3):339-44. PubMed ID: 11241413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary ovarian mucinous tumors with signet ring cells: report of 3 cases with discussion of so-called primary Krukenberg tumor.
    McCluggage WG; Young RH
    Am J Surg Pathol; 2008 Sep; 32(9):1373-9. PubMed ID: 18670351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
    Ayhan A; Guven S; Guven ES; Kucukali T
    Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Numerical abnormalities of chromosomes 1, 11, 17, and X are associated with stromal invasion in serous and mucinous epithelial ovarian tumours.
    Evans MF; McDicken IW; Herrington CS
    J Pathol; 1999 Sep; 189(1):53-9. PubMed ID: 10451488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
    McKenney JK; Soslow RA; Longacre TA
    Am J Surg Pathol; 2008 May; 32(5):645-55. PubMed ID: 18344868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics and prognosis of mucinous tumors of the ovary.
    Kikkawa F; Nawa A; Kajiyama H; Shibata K; Ino K; Nomura S
    Gynecol Oncol; 2006 Oct; 103(1):171-5. PubMed ID: 16546243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignant or borderline mucinous cystic neoplasms have a larger number of loculi than mucinous cystadenoma: a retrospective study with MR.
    Okamoto Y; Tanaka YO; Tsunoda H; Yoshikawa H; Minami M
    J Magn Reson Imaging; 2007 Jul; 26(1):94-9. PubMed ID: 17659568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucinous tumors of the ovary: a review.
    Hart WR
    Int J Gynecol Pathol; 2005 Jan; 24(1):4-25. PubMed ID: 15626914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor.
    Tamakoshi K; Kikkawa F; Shibata K; Tomoda K; Obata NH; Wakahara F; Tokuhashi Y; Ishikawa H; Kawai M; Tomoda Y
    Gynecol Oncol; 1996 Jul; 62(1):67-72. PubMed ID: 8690294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The utility of tumor markers and neutrophil lymphocyte ratio in patients with an intraoperative diagnosis of mucinous borderline ovarian tumor.
    Seckin KD; Karslı MF; Yucel B; Bestel M; Yıldırım D; Canaz E; Akbayır O
    Eur J Obstet Gynecol Reprod Biol; 2016 Jan; 196():60-3. PubMed ID: 26683535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.